Shattuck Labs, Inc. STTK 深 沪
等待开盘 02-10 09:30:00 美东时间
3.97
+0.200
+5.31%
华盛通- 最 高4.07
- 今 开3.80
- 成交量 32.61万股
- 最 低 3.69
- 昨 收 3.77
- 总市值 2.51亿
- 52周最高 4.89
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 0.6922
- 委 比 -65.28%
- 总股本 6327.98万
- 历史最高 60.516
- 量 比 0.81
- 振 幅 10.08%
- 历史最低 0.6922
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Piper Sandler Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $15
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Overweight rating and announces Price Target of $15.
01-28 21:52
Shattuck Labs Files Shelf Registration To Offer Up To $200M Of Common Stock, Preferred Stock, Debt, Warrants And Units
COMMON STOCKPREFERRED STOCKDEBT SECURITIESWARRANTSUNITSFrom time to time, we may issue, in one or more series or classes, up to $200,000,000 in aggregate principal amount of our common stock, preferred stock, debt
01-14 05:22
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Citigroup Maintains Neutral on Shattuck Labs, Raises Price Target to $4
Citigroup analyst Yigal Nochomovitz maintains Shattuck Labs (NASDAQ:STTK) with a Neutral and raises the price target from $2 to $4.
01-07 02:40
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shattuck Labs, a clinical-stage biotech company, announced equity awards for a newly hired non-executive officer on December 10, 2025. The awards include 206,000 non-qualified stock options with an exercise price of $3.23 per share. The options vest 25% on November 17, 2026, and the remainder in monthly installments over 36 months. Shattuck focuses on developing therapies for inflammatory and immune-mediated diseases, including a novel antibody t...
2025-12-15 21:15
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.
2025-12-02 05:33
HC Wainwright & Co. Upgrades Shattuck Labs to Buy, Announces $6 Price Target
HC Wainwright & Co. analyst Joseph Pantginis upgrades Shattuck Labs (NASDAQ:STTK) from Neutral to Buy and announces $6 price target.
2025-12-01 20:18
Shattuck Labs to Participate in Upcoming December Investor Conferences
Shattuck Labs, Inc. announced that its management will participate in two investor conferences in December 2025. The first is the Piper Sandler 37th Annual Healthcare Conference on Dec 2, featuring a presentation by CEO Taylor Schreiber, available via webcast. The second is the Evercore ISI 8th Annual HealthCONx Conference, with a fireside chat on Dec 4. Both events include one-on-one meetings. The company is developing SL-325, a novel DR3 blocki...
2025-11-20 13:00
